Clinical Trials on Refractory Fallopian Tube Endometrioid Adenocarcinoma

Total 915 results

Massachusetts General Hospital

Completed

CRLX101 in Combination With Bevacizumab for Recurrent Ovarian/Tubal/Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cancer

United States
Dana-Farber Cancer Institute
National Comprehensive Cancer Network; AVEO Pharmaceuticals, Inc.

Terminated

Tivozanib As Maintenance Therapy In GYN

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Carcinoma

United States
M.D. Anderson Cancer Center

Terminated

Letrozole in Patients With Ovarian Tumors

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cancer

United States
Liz-Anne Lewsley
Ovarian Cancer Action

Recruiting

Longitudinal Sample Collection to Investigate Adaptation and Evolution of Ovarian High-grade Serous Carcinoma (BriTROC-2)

Ovarian Cancer | Fallopian Tube Cancer | BRCA1 Mutation | BRCA2 Mutation | High Grade Serous Carcinoma | Primary Peritoneal Carcinoma | Carcinosarcoma, Ovarian

United Kingdom
Dana-Farber Cancer Institute
National Cancer Institute (NCI)

Recruiting

Microdevice In Ovarian, Fallopian Tube, And Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cancer | Ovarian Cancer Stage IV | Ovarian Cancer Stage III | Fallopian Tube Cancer Stage IV | Fallopian Tube Cancer Stage III

United States
Charite University, Berlin, Germany
Kliniken Essen-Mitte

Recruiting

KORE-Innovation: a Prospective, Multi-site Clinical Trial to Implement and Analyse the Effects of an Innovative Perioperative Care Pathway to Reduce Complications for Patients With Ovarian Cancer (KORE)

Fallopian Tube Cancer | Frailty | Ovary Cancer | Peritoneum Cancer

Germany
Ludwig Institute for Cancer Research
Roswell Park Cancer Institute; New York University Cancer Institute

Completed

Vaccine Therapy in Stage II, III, or IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cavity Cancer

United States
University of Texas Southwestern Medical Center
AstraZeneca

Terminated

Anti-PD-L1 and SAbR for Ovarian Cancer

Fallopian Tube Cancer | Primary Peritoneal Carcinoma | Recurrent Epithelial Cancer of Ovary

United States
Massachusetts General Hospital
National Cancer Institute (NCI); Genentech, Inc.

Unknown

Intraperitoneal Paclitaxel and Carboplatin With IV Avastin Therapy in Patients With Carcinomas of Mullerian Origin

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cancer

United States
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)

Withdrawn

18F-CP18 Imaging Studies for Cancer Treatment With Birinapant

Ovarian Neoplasms | Fallopian Tube Neoplasms | Ovarian Cancer | Fallopian Tube Cancer
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Docetaxel, Trabectedin, and G-CSF or Pegfilgrastim in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

United States
National University Hospital, Singapore
KK Women's and Children's Hospital; National Cancer Centre, Singapore; Australia...

Unknown

Vinorelbine in Relapsed Platinum Resistant or Refractory C5 High Grade Serous, Endometrioid, or Undifferentiated Primary Peritoneum, Fallopian Tube or Ovarian Cancer

Ovarian Cancer | Fallopian Tube Cancer

Singapore, Australia
AGO Study Group
GERCOR - Multidisciplinary Oncology Cooperative Group; Nordic Society of Gynaecological...

Completed

Carboplatin/Paclitaxel +/-Gemcitabine in Treating Patients With Ovarian Epithelial or Fallopian Tube Cancer (AGO-OVAR9)

Ovarian Cancer | Fallopian Tube Cancer

Norway, Germany, France, Denmark
Fox Chase Cancer Center
National Cancer Institute (NCI)

Withdrawn

Metformin Hydrochloride, Carboplatin, and Paclitaxel in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Ovarian Serous Cystadenocarcinoma | Recurrent Ovarian Epithelial Cancer | Recurrent Primary Peritoneal Cavity Cancer | Recurrent Ovarian Germ Cell Tumor | Ovarian Papillary Serous Carcinoma | Recurrent Fallopian Tube Cancer

United States
National Cancer Institute (NCI)

Active, not recruiting

Gemcitabine Hydrochloride Alone or With M6620 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Serous Tumor

United States
National Cancer Institute (NCI)

Terminated

SJG-136 in Treating Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer That Did Not Respond to Previous Treatment With Cisplatin or Carboplatin

Recurrent Ovarian Epithelial Cancer | Recurrent Primary Peritoneal Cavity Cancer | Recurrent Fallopian Tube Cancer

United States
Translational Research Center for Medical Innovation...
Japanese Gynecologic Oncology Group (JGOG); Department of Obstetrics and Gynecology... and other collaborators

Completed

Homologous Recombination Inquiry Through Ovarian Malignancy Investigations (HITOMI)

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cancer

Japan
National Cancer Institute (NCI)

Completed

Olaparib in Combination With Carboplatin for Refractory or Recurrent Women s Cancers

Breast Cancer | Ovarian Cancer | Fallopian Tube Cancer | Endometrial Cancer | Primary Peritoneal Cancer

United States
Janssen Research & Development, LLC
PharmaMar

Completed

A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Ovarian Neoplasms | Fallopian Tube Neoplasms | Peritoneal Neoplasms

United States, Poland, United Kingdom, China, Switzerland, Israel, South Africa, Australia, Russian Federation, New Zealand
Massachusetts General Hospital
Dana-Farber Cancer Institute; Brigham and Women's Hospital; National Comprehensive...

Completed

Carboplatin/Pralatrexate in Recurrent Platinum-Sensitive Ovarian, Fallopian or Primary Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cancer

United States
University Health Network, Toronto
National Cancer Institute (NCI)

Completed

UCN-01 and Topotecan in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

Canada
NYU Langone Health
National Cancer Institute (NCI)

Completed

Combination Chemotherapy in Treating Patients With Endometrial Cancer, Fallopian Tube Cancer, or Sarcoma of the Female Reproductive Tract

Sarcoma | Ovarian Cancer | Fallopian Tube Cancer | Endometrial Cancer

United States
University of Minnesota

Terminated

Effect of Serotonin Level on Constipation Caused by Chemotherapy in Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Constipation | Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cavity Cancer | Bowel Obstruction

United States
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI); Sanofi; Genentech, Inc.

Completed

Avastin in Combination With Docetaxel in Ovarian/Fallopian Tube/Peritoneum Carcinoma

Ovarian Cancer | Fallopian Tube Cancer | Malignant Tumor of Peritoneum

United States
Medical University Innsbruck

Unknown

Liposome-Encapsulated Doxorubicin Citrate With or Without Gemcitabine Hydrochloride in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

Austria
Korean Gynecologic Oncology Group

Unknown

A Phase IIclinical Trial of Carboplatin and Paclitaxel or Carboplatin and Gemcitabine in Platinum-sensitive, Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cancer

Korea, Republic of
CanariaBio Inc.
Veristat, LLC

Active, not recruiting

A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.

Peritoneal Cancer | Recurrent Ovarian Cancer | Recurrent Fallopian Tube Cancer | Recurrent Epithelial Cancer of Ovary | Recurrent Epithelial Ovarian Cancer | Recurrent Carcinoma of Ovary | Adenocarcinoma of Ovary

United States
Albert Einstein College of Medicine
National Cancer Institute (NCI)

Completed

Pemetrexed and Carboplatin in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma

United States
Roswell Park Cancer Institute
Eisai Inc.

Completed

Decitabine, Vaccine Therapy, and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer

Recurrent Ovarian Epithelial Cancer | Recurrent Primary Peritoneal Cavity Cancer | Recurrent Fallopian Tube Cancer

United States
AGO Study Group

Terminated

Reinduction Chemotherapy Containing Carboplatin and Paclitaxel With or Without Epoetin Alpha in Recurrent Platinum Sensitive Ovarian Cancer, Cancer of the Fallopian Tube or Peritoneum

Anemia | Epithelial Ovarian Cancer, Fallopian Tube or Peritoneum | Platinum Sensitve Relapse

Germany
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer

Pain | Neuropathy | Stage IIIA Fallopian Tube Cancer | Stage IIIA Ovarian Cancer | Stage IIIA Primary Peritoneal Cancer | Stage IIIB Fallopian Tube Cancer | Stage IIIB Ovarian Cancer | Stage IIIB Primary Peritoneal Cancer | Stage IIIC Fallopian Tube Cancer | Stage IIIC Ovarian Cancer | Stage IIIC Primary... and other conditions

United States
University of Pennsylvania
National Cancer Institute (NCI); Alliance for Cancer Gene Therapy; OvaCure Fundation and other collaborators

Terminated

MOv19-BBz CAR T Cells in aFR Expressing Recurrent High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Carcinoma

United States
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Terminated

Docetaxel and Capecitabine in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cavity Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cavity Cancer

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Unknown

Proteomic Profiling in Diagnosing Ovarian Cancer in Patients Who Are Undergoing Surgery for an Abnormal Pelvic Mass

Ovarian Cancer | Fallopian Tube Cancer

United States
Mayo Clinic

Completed

Auranofin in Treating Patients With Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Recurrent Ovarian Epithelial Cancer | Recurrent Primary Peritoneal Cavity Cancer | Recurrent Fallopian Tube Cancer

United States
National Cancer Institute (NCI)

Completed

Cediranib Maleate in Treating Patients With Persistent, Recurrent, or Refractory Advanced Ovarian Epithelial, Peritoneal Cavity, or Fallopian Tube Cancer

Recurrent Ovarian Epithelial Cancer | Recurrent Primary Peritoneal Cavity Cancer | Recurrent Fallopian Tube Cancer

United States, Canada
National Cancer Institute (NCI)

Active, not recruiting

Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Platinum-Resistant Ovarian Carcinoma

United States
Fundacion para la Formacion e Investigacion Sanitarias...

Unknown

Cytoreduction With or Without Intraoperative Intraperitoneal Hyperthermic Chemotherapy (HIPEC) in Patients With Peritoneal Carcinomatosis From Ovarian Cancer, Fallopian Tube or Primary Peritoneal Carcinoma (CARCINOHIPEC)

Fallopian Tube Carcinoma | Primary Peritoneal Carcinoma | Peritoneal Carcinomatosis From Ovarian Cancer

Spain
Masonic Cancer Center, University of Minnesota
National Cancer Institute (NCI)

Not yet recruiting

Intraperitoneal FT536 in Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

Gynecologic Cancer | Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

Recruiting

A Single-arm Clinical Trial of IMGN853 in Chinese Adult Patients With Platinum-resistant, Epithelial Ovarian Cancer

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Peritoneal Cancer

China
Shanghai Gynecologic Oncology Group
Fudan University

Not yet recruiting

Surgery Combined With Maintenance Targeted Therapy in the Treatment of Advanced Ovarian Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Carcinoma

China
ImmunoGen, Inc.
Gynecologic Oncology Group; European Network of Gynaecological Oncological...

Active, not recruiting

A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression (MIRASOL)

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Peritoneal Cancer

United States, Canada, Germany, China, France, Korea, Republic of, Belgium, United Kingdom, Serbia, Spain, Australia, Israel, Italy, Taiwan, Czechia, Bulgaria, Netherlands, Portugal, Poland, Russian Federation, Ukraine
Washington University School of Medicine
Aravive, Inc.

Withdrawn

Paclitaxel + Carboplatin With AVB-S6-500 in Women With Stage III or IV Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Receiving Neoadjuvant Chemotherapy

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Primary Peritoneal Carcinoma
Duke University

Completed

Prospective Randomized Trial of Streamlined Genetic Education and Testing for Ovarian Cancer Patients

Fallopian Tube Cancer | Peritoneal Cancer | Ovarian Cancer, Epithelial

United States
Array Biopharma, now a wholly owned subsidiary...

Completed

A Study of MEK162 and Paclitaxel in Patients With Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Peritoneal Cancer

United States
Kazia Therapeutics Limited

Completed

Phase I Study of Cantrixil in Patients With Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer.

Ovarian Neoplasms | Fallopian Tube Neoplasms | Peritoneal Neoplasms

United States, Australia
Duke University

Completed

The Treatment Preferences of Women Diagnosed With Ovarian Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Carcinoma

United States
University College, London
Boehringer Ingelheim

Completed

Low Dose Cyclophosphamide +/-- Nintedanib in Advanced Ovarian Cancer (METRO-BIBF)

Ovarian Cancer | Fallopian Tube Cancer

United Kingdom
Memorial Sloan Kettering Cancer Center
National Institutes of Health (NIH)

Completed

Outcomes From Home in Patients Recovering From Major Gynecologic Cancer Surgery: Measuring Symptoms and Health-related Quality of Life

Ovarian Cancer | Fallopian Tube Cancer | Vulvar Cancer | Vaginal Cancer | Peritoneal Cancer | Uterine Cancer

United States
Eli Lilly and Company

Completed

A Study of Chemotherapy Treatment for Patients With Ovarian Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cancer

Italy, United States, Russian Federation

Clinical Trials on Refractory Fallopian Tube Endometrioid Adenocarcinoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Jamaica

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations